long intergenic non-protein coding RNA 1915Genealiases: []
Q-omics provides the consensus-scored LINC01915 profile across patient tissues and cancer cell-line models. LINC01915 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, LINC01915 is differentially expressed in 12, with the highest sampling consensus in LUSC. Additionally, LINC01915 RNA expression shows 15,157 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight COAD, LUSC, and UVM as cancer lineages where LINC01915 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01915 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01915 survival associations across molecular data types. LINC01915 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01915 RNA expression–survival associations across cancer types. High LINC01915 expression shows unfavorable associations in KICH and LAML, but favorable associations in COAD, KIRC, LUAD and THYM. The COAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for LINC01915 RNA expression.
This table summarizes LINC01915 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01915. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01915 shows lower tumor expression in LUSC, COAD, KIRP, KIRC, READ and KICH. The LUSC box plot shows higher LINC01915 RNA expression in normal versus tumor tissue (log2 FC = −0.773, t-test p < 0.001).
This table shows molecular features associated with LINC01915 in patient tissues and cancer cell lines. In patient samples, LINC01915 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
